Revenue
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Evolent Health, Inc. (EVH)
Price$4.32Cached quote
Net income
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.88B | $2.55B | $1.96B | $1.35B | $908.0M | $924.6M | $846.4M | $627.1M | $434.9M | $254.2M | $96.9M | $0 | $25.7M |
| Gross profit | $399.9M | $367.4M | $460.5M | $316.6M | $250.4M | $228.1M | — | — | — | — | — | — | — |
| Gross margin | 21.31% | 14.38% | 23.45% | 23.42% | 27.58% | 24.66% | — | — | — | — | — | — | — |
| Research & development | — | — | — | — | $15.5M | $15.1M | $19.8M | $18.2M | $17.2M | $11.1M | $5.8M | $0 | $2.0M |
| Operating expenses | $2.29B | $2.60B | $2.04B | $1.35B | $950.4M | $1.19B | $996.0M | $674.5M | $507.8M | $491.6M | $139.8M | $0 | $46.8M |
| Operating income | −$410.1M | −$40.5M | −$71.2M | $3.6M | −$42.4M | −$262.8M | −$308.9M | −$47.5M | −$72.8M | −$237.4M | −$43.0M | $0 | −$21.2M |
| Operating margin | −21.86% | −1.58% | −3.63% | 0.27% | −4.67% | −28.43% | −36.49% | −7.57% | −16.75% | −93.40% | −44.36% | — | −82.41% |
| EBITDA | −$294.3M | $77.9M | $52.2M | $70.8M | $17.6M | −$201.4M | −$248.0M | −$3.0M | −$40.5M | −$220.2M | −$35.8M | $0 | −$19.9M |
| EBITDA margin | −15.69% | 3.05% | 2.66% | 5.24% | 1.94% | −21.78% | −29.30% | −0.47% | −9.30% | −86.63% | −36.96% | — | −77.70% |
| Net income | −$534.5M | −$61.6M | −$113.0M | −$19.2M | −$37.6M | −$334.2M | −$302.0M | −$52.7M | −$60.7M | −$159.7M | $332.5M | −$25.2M | $20.0M |
| Net profit margin | −28.49% | −2.41% | −5.76% | −1.42% | −4.14% | −36.15% | −35.68% | −8.40% | −13.95% | −62.84% | 343.21% | — | 78.00% |
| Basic EPSper basic share | -$5.07 | -$0.81 | -$1.28 | -$0.20 | -$0.44 | -$3.94 | -$3.67 | -$0.68 | -$0.94 | -$3.55 | $13.14 | -$13.46 | $2.51 |
| Diluted EPSper diluted share | -$5.07 | -$0.81 | -$1.28 | -$0.20 | -$0.44 | -$3.94 | -$3.67 | -$0.68 | -$0.94 | -$3.55 | $6.93 | -$13.46 | $0.99 |
Owners
Reported shareholders
Reported holdings Number of shares
View holders
| Holder | Shares held |
|---|---|
BlackRock, Inc. | 14.81M |
CADIAN CAPITAL MANAGEMENT, LP | 10.81M |
MORGAN STANLEY | 8.97M |
UBS Group AG | 6.25M |
Rubicon Founders LLC | 5.82M |
Engaged Capital LLC | 5.56M |
D. E. Shaw & Co., Inc. | 5.11M |
VANGUARD CAPITAL MANAGEMENT LLC | 4.79M |
MARSHALL WACE, LLP | 3.41M |
Nuveen, LLC | 3.13M |
GEODE CAPITAL MANAGEMENT, LLC | 2.9M |
Rock Springs Capital Management LP | 2.5M |
STATE STREET CORP | 2.46M |
CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 2.13M |
GOLDMAN SACHS GROUP INC | 1.75M |
Rock Point Advisors, LLC | 1.72M |
JACOBS LEVY EQUITY MANAGEMENT, INC | 1.6M |
KENNEDY CAPITAL MANAGEMENT LLC | 1.57M |
VANGUARD PORTFOLIO MANAGEMENT LLC | 1.35M |
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | 1.28M |
Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Nov 18, 2025Form 4 | Springstubb Brendan BDirector | BuyClass A Common Stock | 10.0K | $3.82 | $38.2K | 58.8K |
| Mar 7, 2025Form 4 | Jelinek Richard MDirector | BuyClass A Common Stock · indirect | 15.0K | $9.09 | $136.3K | 15.0K |
| Mar 7, 2025Form 4 | Jelinek Richard MDirector | BuyClass A Common Stock · indirect | 15.0K | $9.16 | $137.4K | 15.0K |
| Mar 7, 2025Form 4 | Springstubb Brendan BDirector | BuyClass A Common Stock | 15.0K | $9.27 | $139.1K | 26.8K |
| Mar 7, 2025Form 4 | KECK KIMDirector | BuyClass A Common Stock | 10.5K | $9.44 | $99.5K | 39.5K |